Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyuki Uchida

Showing results (411-420 of 461) with videos related to

Pageof 47
Sort By:
Schizophrenia Research|March 12, 2015
Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET studyShinichiro Nakajima, Fernando Caravaggio, David C Mamo, et al.
Journal of Psychiatric Research|August 20, 2025
The association between amygdalar volume changes and depressive symptom improvements after repeated ketamine infusion in treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with the following open-label studyKengo Yonezawa, Shinichiro Nakajima, Nobuaki Hondo, et al.
Journal of Psychiatry & Neuroscience : JPN|January 14, 2022
Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levelsRyo Ochi, Eric Plitman, Raihaan Patel, et al.
Neuropsychopharmacology Reports|March 18, 2020
Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophreniaKamiyu Ogyu, Yoshihiro Noda, Kazunari Yoshida, et al.
The Journal of Clinical Psychiatry|January 14, 2017
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With SchizophreniaYusuke Iwata, Shinichiro Nakajima, Fernando Caravaggio, et al.
Cancer Science|August 5, 2020
A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomasNayuta Higa, Toshiaki Akahane, Seiya Yokoyama, et al.
BMC Oral Health|August 21, 2012
Dental conditions in inpatients with schizophrenia: a large-scale multi-site surveyHideaki Tani, Hiroyuki Uchida, Takefumi Suzuki, et al.
British Journal of Neurosurgery|October 15, 2014
Improvement in treatment results of glioblastoma over the last three decades and beneficial factorsHiroto Kawano, Hirofumi Hirano, Hajime Yonezawa, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|January 7, 2026
Hierarchical Brain Dynamics Associated with Remission from Major Depression Across Diverse Therapeutic ModalitiesKazushi Shinagawa, Jinichi Hirano, Yuki Kobayashi, et al.
Neuropsychopharmacology Reports|April 30, 2026
Glutathione-Related Metabolite Levels and Enzyme Activities in Depression: A Systematic Review and Meta-AnalysisTakahide Etani, Nobuaki Hondo, Sho Moriguchi, et al.
Pageof 47

Showing results (411-420 of 461) with videos related to

Sort By:
Pageof 47
Schizophrenia Research|March 12, 2015
Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET studyShinichiro Nakajima, Fernando Caravaggio, David C Mamo, et al.
Journal of Psychiatric Research|August 20, 2025
The association between amygdalar volume changes and depressive symptom improvements after repeated ketamine infusion in treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with the following open-label studyKengo Yonezawa, Shinichiro Nakajima, Nobuaki Hondo, et al.
Journal of Psychiatry & Neuroscience : JPN|January 14, 2022
Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levelsRyo Ochi, Eric Plitman, Raihaan Patel, et al.
Neuropsychopharmacology Reports|March 18, 2020
Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophreniaKamiyu Ogyu, Yoshihiro Noda, Kazunari Yoshida, et al.
The Journal of Clinical Psychiatry|January 14, 2017
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With SchizophreniaYusuke Iwata, Shinichiro Nakajima, Fernando Caravaggio, et al.
Cancer Science|August 5, 2020
A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomasNayuta Higa, Toshiaki Akahane, Seiya Yokoyama, et al.
BMC Oral Health|August 21, 2012
Dental conditions in inpatients with schizophrenia: a large-scale multi-site surveyHideaki Tani, Hiroyuki Uchida, Takefumi Suzuki, et al.
British Journal of Neurosurgery|October 15, 2014
Improvement in treatment results of glioblastoma over the last three decades and beneficial factorsHiroto Kawano, Hirofumi Hirano, Hajime Yonezawa, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|January 7, 2026
Hierarchical Brain Dynamics Associated with Remission from Major Depression Across Diverse Therapeutic ModalitiesKazushi Shinagawa, Jinichi Hirano, Yuki Kobayashi, et al.
Neuropsychopharmacology Reports|April 30, 2026
Glutathione-Related Metabolite Levels and Enzyme Activities in Depression: A Systematic Review and Meta-AnalysisTakahide Etani, Nobuaki Hondo, Sho Moriguchi, et al.
Pageof 47